Drug Plus Diet Cut Weight, Metabolism Woes in Study Funded by Drug's Maker
Nov. 16, 2005 -- A new antiobesity drug, Acomplia, may trim some heart risks along with extra pounds.
So says a year-long study published in The New England Journal of Medicine. The study was funded by Sanofi Aventis, Acomplia's maker. Acomplia is not yet on the market.
Participants didn't just pop pills. They also ate fewer calories every day for a year. Many quit the study early.
Those who stuck with it lost some weight, slimmed their waists, and improved their blood-fat levels. Those taking Acomplia showed bigger improvements, write the researchers.
They included Jean-Pierre Despres, PhD. Despres works at Canada's Quebec Heart Institute at the Laval Hospital Research Center.
Drug Plus Diet
They were randomly assigned to take either an inactive pill (placebo), 5 milligrams of Acomplia, or 20 milligrams of Acomplia daily. No one knew which pill they were taking.
Less than two-thirds finished the study. Here are their weight and waistline losses:
- Placebo: 5.07 pounds and 1.33 inches lost
- Acomplia (lower dose): 9.26 pounds and 1.92 inches lost
- Acomplia (higher dose): 18.96 pounds and 3.58 inches lost
Weight loss happened during the first nine months and leveled off later, the study shows.
All three groups also showed improvements in HDL "good" cholesterol, with the biggest improvements in those taking the higher dose of Acomplia.
All three groups had roughly the same percentage of participants quit the study (37% to 40%).
Dropping out of the study because of side effects was mainly seen in the people taking the higher 20-milligram dose of Acomplia.
Overall, the researchers note that few patients quit over those problems.
The researchers suggest that Acomplia may go above and beyond drug-free weight loss in improving waist size, triglycerides, and cholesterol. However, they don't present Acomplia as a magic bullet against obesity.